Repare Therapeutics Inc is a Canada-based precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations. Its approach integrates discoveries from several fields of cell biology including deoxyribonucleic acid (DNA) repair and synthetic lethality. Its SNIPRx platform combines a clustered regularly interspaced short palindromic repeats (CRISPR)-enabled gene editing target discovery method with protein crystallography, computational biology and clinical informatics.